- Home
- NLSP vs XBIO Comparison
NLSP vs XBIO Comparison
Compare NLSP & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- XBIO
- Stock Information
- Founded
- NLSP 2015
- XBIO N/A
- Country
- NLSP Switzerland
- XBIO United States
- Employees
- NLSP N/A
- XBIO N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- XBIO Health Care
- Exchange
- NLSP Nasdaq
- XBIO Nasdaq
- Market Cap
- NLSP 6.2M
- XBIO 6.3M
- IPO Year
- NLSP 2021
- XBIO N/A
- Fundamental
- Price
- NLSP $1.81
- XBIO $4.28
- Analyst Decision
- NLSP
- XBIO Hold
- Analyst Count
- NLSP 0
- XBIO 1
- Target Price
- NLSP N/A
- XBIO N/A
- AVG Volume (30 Days)
- NLSP 2.2M
- XBIO 10.0K
- Earning Date
- NLSP 10-18-2024
- XBIO 11-12-2024
- Dividend Yield
- NLSP N/A
- XBIO N/A
- EPS Growth
- NLSP N/A
- XBIO N/A
- EPS
- NLSP N/A
- XBIO N/A
- Revenue
- NLSP N/A
- XBIO $2,523,427.00
- Revenue This Year
- NLSP N/A
- XBIO N/A
- Revenue Next Year
- NLSP N/A
- XBIO N/A
- P/E Ratio
- NLSP N/A
- XBIO N/A
- Revenue Growth
- NLSP N/A
- XBIO 7.15
- 52 Week Low
- NLSP $1.73
- XBIO $2.78
- 52 Week High
- NLSP $20.80
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- NLSP 40.38
- XBIO 53.83
- Support Level
- NLSP $1.87
- XBIO $3.93
- Resistance Level
- NLSP $2.08
- XBIO $4.34
- Average True Range (ATR)
- NLSP 0.20
- XBIO 0.22
- MACD
- NLSP 0.01
- XBIO 0.02
- Stochastic Oscillator
- NLSP 2.33
- XBIO 88.68
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.